tiprankstipranks
Cybin to Present Promising CYB003 Study Results
Company Announcements

Cybin to Present Promising CYB003 Study Results

Story Highlights

Cybin (TSE:CYBN) has released an update.

Pick the best stocks and maximize your portfolio:

Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive Disorder during a webcast on November 18, 2024. The event will also highlight the launch of their Phase 3 PARADIGM program for further development of CYB003. With a commitment to innovative mental healthcare solutions, Cybin aims to transform the treatment landscape for mental health conditions.

For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskCybin Reveals Promising Results in Depression Treatment
TipRanks Canadian Auto-Generated NewsdeskCybin to Discuss Breakthrough Treatments at Fireside Chat
TipRanks Auto-Generated NewsdeskCybin Inc. Advances in Mental Health Treatments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App